Logo

Stratagene to Seek Licensing Revenues Following PCR Settlement

May 16, 2006

NEW YORK, May 16 (GenomeWeb News) - Stratagene said today that its recent settlement of a patent dispute with Takara Bio related to PCR enzyme blends has "significantly strengthened its patent portfolio" in this area.

 

As such, Stratagene said, it now owns a broad USpatent portfolio covering its enzyme blends, and will seek to establish a licensing program for competitors' products covered by the portfolio.

 

"We believe that there are a number of competitors selling products that are covered under our patent portfolio," Joseph Sorge, president and CEO of Stratagene, said in a statement. "It is our intention to make limited licenses available and recognize resulting licensing revenue."

 

As GenomeWeb News reported last week, Stratagene and Takara Bio have reached a settlement under which the firms have agreed to pay "reasonable" royalties to each other under certain licensed patents, and each company will be free to independently license its patents to third parties.

Breaking News
The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.